JP2024520481A - チェックポイントキナーゼ１（ｃｈｋ１）阻害剤およびその使用 - Google Patents
チェックポイントキナーゼ１（ｃｈｋ１）阻害剤およびその使用 Download PDFInfo
- Publication number
- JP2024520481A JP2024520481A JP2023573047A JP2023573047A JP2024520481A JP 2024520481 A JP2024520481 A JP 2024520481A JP 2023573047 A JP2023573047 A JP 2023573047A JP 2023573047 A JP2023573047 A JP 2023573047A JP 2024520481 A JP2024520481 A JP 2024520481A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharma
- tautomer
- stereoisomer
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163193990P | 2021-05-27 | 2021-05-27 | |
| US63/193,990 | 2021-05-27 | ||
| PCT/US2022/031141 WO2022251502A1 (en) | 2021-05-27 | 2022-05-26 | Checkpoint kinase 1 (chk1) inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520481A true JP2024520481A (ja) | 2024-05-24 |
| JP2024520481A5 JP2024520481A5 (enExample) | 2025-06-02 |
Family
ID=84229213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023573047A Pending JP2024520481A (ja) | 2021-05-27 | 2022-05-26 | チェックポイントキナーゼ１（ｃｈｋ１）阻害剤およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11707462B2 (enExample) |
| EP (1) | EP4347582A4 (enExample) |
| JP (1) | JP2024520481A (enExample) |
| KR (1) | KR20240021188A (enExample) |
| CN (1) | CN117715905A (enExample) |
| AU (1) | AU2022282384A1 (enExample) |
| BR (1) | BR112023024571A2 (enExample) |
| CA (1) | CA3219348A1 (enExample) |
| IL (1) | IL308759A (enExample) |
| MX (1) | MX2023014028A (enExample) |
| TW (1) | TW202313588A (enExample) |
| WO (1) | WO2022251502A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4196614A4 (en) | 2020-08-12 | 2024-12-18 | Boundless Bio, Inc. | COMPOSITIONS OF REPLICATION STRESS SIGNAL PATHWAYS AND METHODS FOR TREATING CANCER |
| MX2023006364A (es) | 2020-11-30 | 2023-06-13 | Sumitomo Pharma Co Ltd | Derivado de 5-heteroaril-1h-pirazol-3-amina. |
| JP2024520481A (ja) | 2021-05-27 | 2024-05-24 | バウンドレス バイオ，インク． | チェックポイントキナーゼ１（ｃｈｋ１）阻害剤およびその使用 |
| EP4455134A4 (en) * | 2021-12-24 | 2025-10-08 | Sumitomo Pharma Co Ltd | 1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING A BICYCLIC SKELETON |
| IL317138A (en) * | 2022-05-24 | 2025-01-01 | Boundless Bio Inc | Pyridine checkpoint kinase 1 (CHK1) inhibitors and their uses |
| WO2023226658A1 (en) * | 2022-05-25 | 2023-11-30 | Sperogenix Therapeutics Limited | Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereof |
| TW202440549A (zh) * | 2022-11-29 | 2024-10-16 | 美商無界生物公司 | 檢查點激酶１（ｃｈｋ１）抑制劑及其用途 |
| EP4626433A1 (en) * | 2022-11-29 | 2025-10-08 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof |
| WO2024196923A1 (en) * | 2023-03-20 | 2024-09-26 | Boundless Bio, Inc. | Uses of a checkpoint kinase 1 (chk1) inhibitor |
| WO2024211271A1 (en) * | 2023-04-03 | 2024-10-10 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition |
| WO2024211270A1 (en) * | 2023-04-03 | 2024-10-10 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor crystalline form and uses thereof |
| WO2025030049A1 (en) * | 2023-08-02 | 2025-02-06 | Health Research, Inc. | Sequential treatment method for p53-deficient cancer |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004501083A (ja) * | 2000-04-18 | 2004-01-15 | アゴーロン・ファーマシューティカルズ・インコーポレイテッド | プロテインキナーゼを阻害するためのピラゾール |
| JP2004507526A (ja) * | 2000-08-31 | 2004-03-11 | ファイザー・プロダクツ・インク | ピラゾール誘導体及びそのプロテインキナーゼ阻害剤としての使用 |
| JP2017508787A (ja) * | 2014-02-10 | 2017-03-30 | カスカディアン セラピューティクス， インコーポレイテッド | 医薬化合物 |
| JP2019509990A (ja) * | 2016-02-04 | 2019-04-11 | ファーマエンジン インコーポレーテッドＰｈａｒｍａｅｎｇｉｎｅ， Ｉｎｃ． | チェックポイントキナーゼ１（ｃｈｋ１）阻害剤として有用な３，５−二置換ピラゾール、並びにその調製及び用途 |
| WO2021019514A1 (en) * | 2019-08-01 | 2021-02-04 | Integral Biosciences Pvt. Ltd. | Heterocyclic compounds as kinase inhibitor and uses thereof |
| WO2021043208A1 (en) * | 2019-09-06 | 2021-03-11 | Impact Therapeutics, Inc | 3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof |
| WO2021253095A1 (en) * | 2020-06-19 | 2021-12-23 | Anaxis Pharma Pty Ltd | Sulphonamide compounds |
| WO2022114189A1 (ja) * | 2020-11-30 | 2022-06-02 | 住友ファーマ株式会社 | ５－ヘテロアリール－１ｈ－ピラゾール－３－アミン誘導体 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050209297A1 (en) * | 2000-08-31 | 2005-09-22 | Pfizer Inc | Pyrazole derivatives |
| PA8850801A1 (es) * | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
| CN111253370B (zh) | 2020-03-24 | 2021-08-03 | 浙江大学 | N-多取代吡啶-2-氨基嘧啶类衍生物及用途 |
| EP4196614A4 (en) | 2020-08-12 | 2024-12-18 | Boundless Bio, Inc. | COMPOSITIONS OF REPLICATION STRESS SIGNAL PATHWAYS AND METHODS FOR TREATING CANCER |
| JP2023547396A (ja) | 2020-10-23 | 2023-11-10 | セルジーン コーポレーション | 蠕虫感染及び疾患の処置のための複素環式化合物及びその使用 |
| US11564920B2 (en) | 2020-11-30 | 2023-01-31 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1H-pyrazol-3-amine derivative |
| JP2024520481A (ja) | 2021-05-27 | 2024-05-24 | バウンドレス バイオ，インク． | チェックポイントキナーゼ１（ｃｈｋ１）阻害剤およびその使用 |
| EP4455134A4 (en) | 2021-12-24 | 2025-10-08 | Sumitomo Pharma Co Ltd | 1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING A BICYCLIC SKELETON |
| IL317138A (en) | 2022-05-24 | 2025-01-01 | Boundless Bio Inc | Pyridine checkpoint kinase 1 (CHK1) inhibitors and their uses |
| WO2023226658A1 (en) | 2022-05-25 | 2023-11-30 | Sperogenix Therapeutics Limited | Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereof |
| CN119403571A (zh) | 2022-05-27 | 2025-02-07 | 住友制药株式会社 | 对免疫检查点抑制剂示出治疗抗性的癌症的治疗药 |
| TW202440549A (zh) | 2022-11-29 | 2024-10-16 | 美商無界生物公司 | 檢查點激酶１（ｃｈｋ１）抑制劑及其用途 |
| EP4626433A1 (en) | 2022-11-29 | 2025-10-08 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof |
| WO2024196923A1 (en) | 2023-03-20 | 2024-09-26 | Boundless Bio, Inc. | Uses of a checkpoint kinase 1 (chk1) inhibitor |
| WO2024211271A1 (en) | 2023-04-03 | 2024-10-10 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition |
| WO2024211270A1 (en) | 2023-04-03 | 2024-10-10 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor crystalline form and uses thereof |
-
2022
- 2022-05-26 JP JP2023573047A patent/JP2024520481A/ja active Pending
- 2022-05-26 AU AU2022282384A patent/AU2022282384A1/en active Pending
- 2022-05-26 IL IL308759A patent/IL308759A/en unknown
- 2022-05-26 BR BR112023024571A patent/BR112023024571A2/pt unknown
- 2022-05-26 TW TW111119737A patent/TW202313588A/zh unknown
- 2022-05-26 CA CA3219348A patent/CA3219348A1/en active Pending
- 2022-05-26 EP EP22812165.3A patent/EP4347582A4/en active Pending
- 2022-05-26 WO PCT/US2022/031141 patent/WO2022251502A1/en not_active Ceased
- 2022-05-26 CN CN202280052765.2A patent/CN117715905A/zh active Pending
- 2022-05-26 MX MX2023014028A patent/MX2023014028A/es unknown
- 2022-05-26 KR KR1020237044236A patent/KR20240021188A/ko active Pending
- 2022-08-29 US US17/897,667 patent/US11707462B2/en active Active
-
2023
- 2023-06-01 US US18/327,775 patent/US12527790B2/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004501083A (ja) * | 2000-04-18 | 2004-01-15 | アゴーロン・ファーマシューティカルズ・インコーポレイテッド | プロテインキナーゼを阻害するためのピラゾール |
| JP2004507526A (ja) * | 2000-08-31 | 2004-03-11 | ファイザー・プロダクツ・インク | ピラゾール誘導体及びそのプロテインキナーゼ阻害剤としての使用 |
| JP2017508787A (ja) * | 2014-02-10 | 2017-03-30 | カスカディアン セラピューティクス， インコーポレイテッド | 医薬化合物 |
| JP2019509990A (ja) * | 2016-02-04 | 2019-04-11 | ファーマエンジン インコーポレーテッドＰｈａｒｍａｅｎｇｉｎｅ， Ｉｎｃ． | チェックポイントキナーゼ１（ｃｈｋ１）阻害剤として有用な３，５−二置換ピラゾール、並びにその調製及び用途 |
| WO2021019514A1 (en) * | 2019-08-01 | 2021-02-04 | Integral Biosciences Pvt. Ltd. | Heterocyclic compounds as kinase inhibitor and uses thereof |
| WO2021043208A1 (en) * | 2019-09-06 | 2021-03-11 | Impact Therapeutics, Inc | 3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof |
| WO2021253095A1 (en) * | 2020-06-19 | 2021-12-23 | Anaxis Pharma Pty Ltd | Sulphonamide compounds |
| WO2022114189A1 (ja) * | 2020-11-30 | 2022-06-02 | 住友ファーマ株式会社 | ５－ヘテロアリール－１ｈ－ピラゾール－３－アミン誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| US12527790B2 (en) | 2026-01-20 |
| MX2023014028A (es) | 2023-12-12 |
| BR112023024571A2 (pt) | 2024-02-06 |
| CN117715905A (zh) | 2024-03-15 |
| CA3219348A1 (en) | 2022-12-01 |
| TW202313588A (zh) | 2023-04-01 |
| KR20240021188A (ko) | 2024-02-16 |
| US11707462B2 (en) | 2023-07-25 |
| WO2022251502A1 (en) | 2022-12-01 |
| EP4347582A1 (en) | 2024-04-10 |
| US20230310423A1 (en) | 2023-10-05 |
| IL308759A (en) | 2024-01-01 |
| EP4347582A4 (en) | 2025-05-07 |
| US20230026313A1 (en) | 2023-01-26 |
| AU2022282384A1 (en) | 2023-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12527790B2 (en) | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | |
| AU2023275712A1 (en) | Pyridine checkpoint kinase 1 (chk1) inhibitors and uses thereof | |
| WO2024118564A1 (en) | Checkpoint kinase 1 (chk1) inhibitors and uses thereof | |
| JP7607841B1 (ja) | Ｐａｒｐ１阻害薬及びその使用 | |
| IL282732B (en) | Salt form of human histone methyltransferase inhibitor 2ezh | |
| JP2024534420A (ja) | 環状スルホンアミドリボヌクレオチドレダクターゼ（ｒｎｒ）阻害剤およびその使用 | |
| EP4301735A1 (en) | Ribonucleotide reductase (rnr) inhibitors and uses thereof | |
| JP2024534421A (ja) | スルファミドリボヌクレオチドレダクターゼ（ｒｎｒ）阻害剤およびその使用 | |
| EP4626433A1 (en) | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof | |
| US20260138968A1 (en) | Pyridine checkpoint kinase 1 (chk1) inhibitors and uses thereof | |
| EA051928B1 (ru) | Пиридиновые ингибиторы киназы 1 контрольной точки (chk1) и их применение | |
| BR112024014920B1 (pt) | Inibidores de parp1, composições que os compreendem, e usos dos mesmos | |
| JP2025531147A (ja) | 環状スルホンアミドリボヌクレオチドレダクターゼ（ｒｎｒ）阻害剤およびその使用 | |
| BR122025009667A2 (pt) | Inibidores de parp1, composições que os compreendem, e usos dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240328 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250523 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250523 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260304 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260312 |